Vanda Pharmaceuticals | VNDA - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
Acadia Pharmaceuticals USD 1.25B 20.68M 2026-03
Agios Pharmaceuticals USD 1.11B 84M 2026-03
Akebia Therapeutics USD 27.38M 5.24M 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Anika Therapeutics USD 133.9M 9.56M 2026-03
Arrowhead Research USD 613.98M 45.56M 2026-03
AstraZeneca USD 47.33B 1.33B 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Eli Lilly USD 31.2B 4.66B 2026-03
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Esperion Therapeutics USD -307.93M 5.97M 2026-03
Halozyme Therapeutics USD 219.64M 170.82M 2026-03
Heron Therapeutics USD 9.14M 4.15M 2026-03
Insmed USD 704.85M 34.12M 2026-03
J&J USD 81.19B 358M 2026-03
Lexicon Pharmaceuticals USD 202.86M 95.32M 2026-03
Ligand Pharmaceuticals USD 997.32M 19.89M 2026-03
Merck USD 45.88B 6.73B 2026-03
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Moderna USD 7.41B 1.24B 2026-03
Novartis USD 46.13B 1.8B 2025-12
Pfizer USD 90.1B 3.63B 2026-03
PTC Therapeutics USD -180.46M 24.85M 2026-03
Puma Biotechnology USD 115.27M 10.55M 2025-09
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 72.81B 1.1B 2026-03
Takeda JPY 7.77T 129.5B 2026-03
Teva Pharmaceutical Industries USD 8.23B 314M 2026-03
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12
Veracyte USD 1.34B 34.83M 2026-03